ARGX argenx SE
ARGX argenx SE
Healthcare · Biotechnology
Desk view
Market read
Scan convergence 1 scan as of 2026-08-17 1 neutral converging
POC $842.01 · VWAP $813.35 · +21.4% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Coverage
ARGX Price Structure
Loading timeframes…
Peers
Every watchlist ARGX belongs to, members best 30-day change first — ARGX highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@focus
Against street estimates
How ARGX's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
Recent news
Headlines about ARGX from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 3 days ago · Aug 15
- argenx (NASDAQ:ARGX) to Acquire Forte Biosciences (NASDAQ:FBRX) in $2.2 Billion Immunology Push
- ARGX: $2.2B acquisition adds FB102, expanding the immunology pipeline into major autoimmune diseases
- argenx Acquires Forte Biosciences for $2.2 Billion
- argenx to Acquire Forte Biosciences, Inc - Adding First-in-Class Anti-CD122 Antibody FB102 to Its Immunology Pipeline
- ARGX Press Release: argenx to Acquire Forte Biosciences, Inc
ARGX research tape
8 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.